<DOC>
	<DOCNO>NCT00671671</DOCNO>
	<brief_summary>Phase 1 study HVC ( Hepatitis C Virus ) infect subject determine pharmacokinetics , safety efficacy subject inadequate response prior treatment .</brief_summary>
	<brief_title>Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>HCV Positive With HCV RNA &gt; 100,000 iu/ml Genotype 1 ; COHORT A non responder partial HIV HBV coinfection Decompensated liver disease Liver disease due cause HCV , AFP &gt; 200ng/ml</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>